Principal Scientist
Genentech
Dr. Michael Z. Liao, Ph.D. MLS (Mike) is currently a Principal Scientist at the Clinical Pharmacology department at Genentech, supporting ADC and Bispecific antibodies development. He recently contributed to the global approval of POLIVY in Previously Untreated and in Relapsed/Refractory DLBCL. Before Genentech, Mike led the clinical pharmacology development of tarlatamab, acapatamab, IMLYGIC, and Vectibix at Amgen. Before Amgen, Mike completed an ORISE fellowship at the FDA in the office of clinical pharmacology and investigated anti-infective agents Phase 2 dose optimization. Before the FDA fellowship, he earned his Ph.D. degree in Pharmaceutics focused on clinical/nonclinical PK-PD from the school of Pharmacy at the University of Washington. B.S. in Medical Laboratory Science at the School of Medicine at the University of Washington. Mike has been a member of ASCPT since 2018 and has chaired the ASCPT EDDS community.
Hi Cancer, We Come Bearing Gifts, Antibody-Drug Conjugate
Thursday, March 23, 2023
9:30 AM – 10:30 AM EDT